|
76
|
294
|
5fp6A |
Structure of cyclin-dependent kinase 2 with small-molecule ligand 3-(4,7-dichloro-1h-indol-3-yl)prop-2-yn-1-ol (at17833) in an alternate binding site. |
|
90
|
276
|
5av1A |
Crystal structure of dapk1 in the presence of bromide ions. |
|
83
|
306
|
5fdxA |
Structure of ddr1 receptor tyrosine kinase in complex with d2164 inhibitor at 2.65 angstroms resolution. |
|
86
|
268
|
5eykA |
Crystal structure of aurora b in complex with bi 847325 |
|
97
|
309
|
5ftoA |
Crystal structure of the alk kinase domain in complex with entrectinib |
|
75
|
302
|
5fm2A |
Crystal structure of hyper-phosphorylated ret kinase domain with (proximal) juxtamembrane segment |
|
79
|
273
|
5fd2A |
B-raf wild-type kinase domain in complex with a purinylpyridinylamino-based inhibitor |
|
90
|
276
|
5auxA |
Crystal structure of dapk1 in complex with kaempferol. |
|
75
|
262
|
4ztsA |
Human aurora a catalytic domain bound to fk1142 |
|
98
|
297
|
4ztnA |
Irak4-inhibitor co-structure |
|
102
|
362
|
5fgkA |
Cdk8-cycc in complex with 8-[3-(3-amino-1h-indazol-6-yl)-5-chloro- pyridine-4-yl]-2,8-diaza-spiro[4.5]decan-1-one |
|
89
|
276
|
5auzA |
Crystal structure of dapk1 in complex with genistein. |
|
97
|
346
|
5f94A |
Crystal structure of gsk3b in complex with compound 15: 2-[(cyclopropylcarbonyl)amino]-n-(4-methoxypyridin-3-yl)pyridine-4-carboxamide |
|
93
|
294
|
5fqdC |
Structural basis of lenalidomide induced ck1a degradation by the crl4crbn ubiquitin ligase |
|
92
|
276
|
5av3A |
Crystal structure of dapk1-kaempferol complex in the presence of iodide ions. |
|
70
|
262
|
4ztrA |
Human aurora a catalytic domain bound to fk1141 |
|
81
|
341
|
5eymA |
Mek1 in complex with bi 847325 |
|
100
|
301
|
5friA |
Alk5 in complex witha an n-(4-anilino-2-pyridyl)acetamide inhibitor. |
|
89
|
303
|
5flfA |
Disease linked mutation in fgfr |
|
89
|
276
|
5av0A |
Crystal structure of dapk1 in complex with 7,3',4'-trihydroxyisoflavone. |
|
88
|
269
|
5fg8A |
Drosophila camkii-wt in complex with a fragment of the eag potassium channel and mg2+/adp |
|
87
|
276
|
5auyA |
Crystal structure of dapk1 in complex with morin. |
|
115
|
350
|
4zthA |
Structure of human p38amapk-arylpyridazinylpyridine fragment complex used in inhibitor discovery |
|
85
|
321
|
5feqA |
Egfr kinase domain in complex with a covalent aminobenzimidazole |
|
71
|
305
|
5fm3A |
Crystal structure of hyper-phosphorylated ret kinase domain with (proximal) juxtamembrane segment |
|
92
|
276
|
5auvA |
Crystal structure of dapk1 in complex with apigenin. |
|
91
|
302
|
5e8yA |
Tgf-beta receptor type 2 kinase domain (e431a,r433a,e485a,k488a,r493a,r495a) in complex with staurosporine |
|
87
|
324
|
5em7A |
Egfr kinase domain mutant "tmlr" with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
|
76
|
298
|
5anoA |
Crystal structure of cdk2 processed with the crystaldirect automated mounting and cryo-cooling technology |
|
83
|
279
|
5ehoA |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
96
|
331
|
5efqA |
Crystal structure of human cdk13/cyclin k in complex with adp-aluminum fluoride |
|
93
|
292
|
5f1zA |
Structure of tyk2 with inhibitor 16: 3-azanyl-5-[(2~{s})-3-methylbutan-2-yl]-7-[1-methyl-5-(2-oxidanylpropan-2-yl)pyrazol-3-yl]-1~{h}-pyrazolo[4,3-c]pyridin-4-one |
|
90
|
322
|
5edpA |
Egfr kinase (t790m/l858r) apo |
|
86
|
264
|
5ew9A |
Crystal structure of aurora a kinase domain bound to mk-5108 |
|
72
|
280
|
5ap5A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
117
|
376
|
5eqpA |
Crystal structure of choline kinase alpha-1 bound by 6-[(4-methyl-1,4-diazepan-1-yl)methyl]quinoline (compound 37) |
|
99
|
304
|
5e8xA |
Tgf-beta receptor type 1 kinase domain (t204d,i211v,y249f,s280t, y282f,s287n,a350c,l352f) in complex with staurosporine |
|
94
|
290
|
5ek7A |
Structure of the autoinhibited epha2 jms-kd |
|
103
|
303
|
5e90A |
Tgf-beta receptor type 1 kinase domain (t204d,i211v,y249f, s280t,y282f,s287n,a350c,l352f) in complex with 3-amino-6- [4-(2-hydroxyethyl)phenyl]-n-[4-(morpholin-4-yl)pyridin-3-yl]pyrazine-2-carboxamide |
|
93
|
323
|
5em6A |
Egfr kinase domain mutant "tmlr" with pyridone compound 19: 4-[(2-azanylpyrimidin-4-yl)amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
|
112
|
356
|
4z9lA |
The structure of jnk3 in complex with an imidazole-pyrimidine inhibitor |
|
79
|
280
|
5ehyA |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
74
|
279
|
5eh0A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
92
|
302
|
5ew8A |
Fibroblast growth factor receptor 1 in complex with jnj-4275693 |
|
86
|
322
|
5edqA |
Egfr kinase (t790m/l858r) with inhibitor compound 15: ~{n}-(7-chloranyl-1~{h}-indazol-3-yl)-7,7-dimethyl-2-(1~{h}-pyrazol-4-yl)-5~{h}-furo[3,4-d]pyrimidin-4-amine |
|
110
|
355
|
5etiA |
Structure of dead kinase mapk14 |
|
76
|
279
|
5ap3A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
121
|
376
|
5eqyA |
Crystal structure of choline kinase alpha-1 bound by 5-[(4-methyl-1,4-diazepan-1-yl)methyl]-2-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]benzenecarbonitrile (compound 65) |
|
78
|
280
|
5ap0A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
84
|
280
|
5ei8A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
